Compass reports CTX-009 Phase 2a ORR 29% in BTC; proposes public offering and Nasdaq uplist

Compass Therapeutics, Inc.

CTX-009 Phase 2a in biliary tract cancer met criteria to advance; 5 partial responses in 17 patients (ORR 29%), 100% clinical benefit rate.
Compass plans to submit US IND this quarter, initiate Phase 2 study in Q2 2022.
Preliminary cash $25.5M as of Sep 30, 2021; proposes underwritten public offering of common stock plus 15% option for underwriters.
Common stock approved for Nasdaq Capital Market listing under symbol CMPX, subject to offering pricing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.